

THIS OFFERING IS AVAILABLE ONLY TO INVESTORS WHO ARE: (1) QUALIFIED INSTITUTIONAL BUYERS ("QIBS") PURCHASING IN RELIANCE ON THE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE US SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), PROVIDED BY RULE 144A THEREUNDER OR PURSUANT TO ANOTHER EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OR (2) OUTSIDE THE UNITED STATES IN COMPLIANCE WITH REGULATION S UNDER THE SECURITIES ACT.

IMPORTANT: You must read the following disclaimer before continuing. The following disclaimer applies to the attached supplement (the "Document") following this page. You are advised to read this disclaimer carefully before accessing, reading or making any other use of the attached Document. In accessing the Document, you agree to be bound by the following terms and conditions, including any modifications to them from time to time, each time you receive any information from us as a result of such access.

IF YOU DO NOT AGREE TO THE TERMS DESCRIBED IN THIS NOTICE, YOU MAY NOT READ, ACCESS OR OTHERWISE USE THE ATTACHED DOCUMENT.

THE OFFER GDRS HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT, OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES AND MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND ANY APPLICABLE STATE OR LOCAL SECURITIES LAWS.

YOU ARE NOT AUTHORIZED TO AND MAY NOT FORWARD OR DELIVER THE ATTACHED DOCUMENT, ELECTRONICALLY OR OTHERWISE, TO ANY OTHER PERSON OR REPRODUCE SUCH DOCUMENT IN ANY MANNER WHATSOEVER. FAILURE TO COMPLY WITH THIS DIRECTIVE MAY RESULT IN A VIOLATION OF THE SECURITIES ACT OR THE APPLICABLE LAWS OF OTHER JURISDICTIONS.

CONFIRMATION OF YOUR REPRESENTATION: The attached Document is being sent at your request and by accepting this e-mail and accessing this Document, you shall be deemed to have represented to us that: (1) you and any customers you represent are (a) QIBs; or (b) outside the United States as defined in Regulation S under the Securities Act and that the e-mail address to which this Document has been delivered is not located in the United States, its territories, possessions (including Puerto Rico, the US Virgin Islands, Guam, American Samoa, Wake Island and the Northern Mariana Islands) and other areas subject to its jurisdiction, and, to the extent you purchase the securities described in the attached Document, you will be doing so in an offshore transaction in reliance on Regulation S under the Securities Act; and (2) you consent to delivery of the attached Document and any amendments or supplements thereto by electronic transmission.

You are reminded that this Document has been delivered to you on the basis that you are a person into whose possession this Document may be lawfully delivered in accordance with the laws of the jurisdiction in which you are located, and you may not nor are you authorized to forward or deliver the attached Document, electronically or otherwise, to any other person. If you receive the attached Document by e-mail, you should not reply by e-mail to this announcement. Any reply e-mail communications, including those you generate by using the "Reply" function on your e-mail software, will be ignored or rejected. If you receive the attached Document by e-mail, your use of this e-mail is at your own risk and it is your responsibility to take precautions to ensure that it is free from viruses and other items of a destructive nature.

The materials relating to the offering do not constitute, and may not be used in connection with, an offer or solicitation in any place where offers or solicitations are not permitted by law. No action has been or will be taken in any jurisdiction by any of Lepu Medical Technology (Beijing) Co., Ltd. (the "Company"), and Credit Suisse AG, CLSA Limited and China International Capital Corporation (UK) Limited (together, the "Joint Global Coordinators"), and China Galaxy International Securities (Hong Kong) Co., Limited, Huatai Financial Holdings (Hong Kong) Limited, and Haitong International Securities Company Limited (together with the Joint Global Coordinators, the "Joint Bookrunners") (or, where applicable in any jurisdiction that requires the offering to be made by a licensed broker or dealer, by such affiliates as are licensed in that jurisdiction for such purpose) that would or is intended to, permit a public offering of the securities, or possession or distribution of the attached Document (in preliminary, proof or final form) or any other offering or publicity material relating to the securities, in any country or jurisdiction where action for that purpose is required. If a jurisdiction requires that the offering be made by a licensed broker or dealer and the Joint Bookrunners or any affiliate of the Joint Bookrunners is a licensed broker or dealer in that jurisdiction, the offering shall be deemed to be made by the Joint Bookrunners or such affiliate on behalf of the Company in such jurisdiction.

In Switzerland, Offer GDRs will be offered solely to professional clients within the meaning of article 4 para 3 of Swiss Financial Services Act, as amended ("FinSA"). The Offer GDRs may not be publicly offered, directly or indirectly, in Switzerland within the meaning of FinSA. Each purchaser of the GDRs in Switzerland will be deemed to have represented and agreed that it qualifies as a "professional client" within the meaning of FinSA.

The attached Document is only addressed to and directed at persons in member states of the European Economic Area (the "EEA") who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") ("**Qualified Investors**"). In addition, in the United Kingdom, the attached Document is being distributed only to, and is directed only at, persons who are "qualified investors" within the meaning of Article 2 of the Prospectus Regulation (Regulation (EU) 2017/1129) as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018 and who: (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "**Order**"); (ii) are high-net-worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are otherwise persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "**relevant persons**"). The attached Document is directed only at relevant persons in the United Kingdom and Qualified Investors in any member state of the EEA and must not be acted on or relied on: (i) in the United Kingdom, by persons who are not relevant persons; and (ii) in any member state of the EEA, by persons who are not Qualified Investors. Any investment or investment activity to which the attached Document relates is available only to: (i) in the United Kingdom, relevant persons; and (ii) in any member state of the EEA, Qualified Investors, and will be engaged in only with such persons.



Lepu Medical Technology (Beijing) Co., Ltd.

(a joint stock company established under the laws of the People's Republic of China with limited liability)

Supplement dated September 15, 2022 to the Prospectus dated September 15, 2022

Offering of up to 11,910,286 Global Depositary Receipts representing A Shares in a base offering and up to an additional 5,774,110 Global Depositary Receipts representing A Shares pursuant to an Upsize Option at an Offer Price expected to be between US\$12.31 and US\$12.68 per Global Depositary Receipt

This document is a supplement (the "**Supplement**") to the prospectus dated September 15, 2022 (the "**Prospectus**") of Lepu Medical Technology (Beijing) Co., Ltd. (the "**Company**"). All definitions used in this Supplement and not otherwise defined herein have the meaning ascribed to them in the Prospectus.

The Prospectus is prepared in accordance with FinSA and its implementing ordinance for the purposes of offering the GDRs and listing the GDRs on SIX Swiss Exchange in accordance with the Standard for Depositary Receipts and was approved on September 15, 2022 by the Review Body. It relates to the Offering, which consists of: (i) a private placement in Switzerland solely to professional clients within the meaning of article 4 para 3 of FinSA; (ii) an offering in the United States only to QIBs as defined in, and in reliance on, Rule 144A, or another exemption from, or in a transaction not subject to, the registration requirements of the Securities Act; and (iii) private placements in certain jurisdictions outside of Switzerland and the United States in accordance with applicable securities laws and on the basis of various exemptions, including those provided by the Prospectus Regulation and the UK Prospectus Regulation. All offers and sales outside the United States will be made in compliance with Regulation S. It also relates to the listing of Offer GDRs on SIX Swiss Exchange in accordance with the Standard for Depositary Receipts.

GDRs sold.....	17,684,396
Final Offer Price.....	US\$12.68 per GDR
Gross proceeds.....	The gross proceeds from the Offering receivable by the Company are approximately US\$224.2 million
Net proceeds.....	The net proceeds from the Offering receivable by the Company are approximately US\$218.0 million, after deducting the total fees (including underwriting commissions, assuming the discretionary fee is paid in full), costs and expenses payable by it in connection with the Offering (inclusive of VAT).
Number of A-Shares following the Offering	1,893,012,089 (based on the Company's share capital as of the Latest Practicable Date)
Total number of GDRs listed	36,091,775 (comprising the 17,684,396 GDRs sold in the Offering and additional GDRs that may be issued from time to time against the deposit of A Shares with the Depositary (to the extent permitted by applicable laws, regulations and regulatory approvals))
Listing and First Day of Trading...	September 21, 2022

Payment, Delivery and Settlement.	Payment for the GDRs is expected to be made in US dollars in same day funds against delivery of the GDRs through the facilities of DTC, in the case of Rule 144A GDRs, and Euroclear and Clearstream, in the case of Regulation S GDRs, on or about September 21, 2022.	
Security Codes.....	Rule 144A GDR ISIN:	US52678P1066
	Rule 144A GDR Common Code:	253299525
	Rule 144A GDR CUSIP	52678P106
	Rule 144A Swiss Security Number (<i>Valorennummer</i>):	121526184
	Regulation S GDR ISIN:	US52678P2056
	Regulation S GDR Common Code:	253303107
	Regulation S GDR CUSIP:	52678P205
	Regulation S Swiss Security Number (<i>Valorennummer</i>):	121526183
	SIX Swiss Exchange ticker symbol:	LEPU
	A Shares ISIN:	CNE100000H44
	Shenzhen Stock Exchange stock code:	300003.SZ

The Prospectus is completed by this Supplement in accordance with the Listing Rules. The Supplement is an integral part of the Prospectus and the Prospectus and this Supplement jointly constitute the final prospectus. This Supplement must be read in conjunction with the Prospectus, including without limitation, the risk factors described in "*Risk Factors*" and "*Selling and Transfer Restrictions*" of the Prospectus. The GDRs have not been and will not be registered under the Securities Act, or with any securities regulatory authority of any state or other jurisdiction in the United States, and may not be offered or sold, directly or indirectly, within the United States except to qualified institutional buyers as defined in and pursuant to Rule 144A under the Securities Act or pursuant to another applicable exemption from, or in a transaction not subject to, the registration requirement of the Securities Act. This Supplement constitutes neither an offer to sell nor a solicitation to buy securities of the Company. The Offer Period ended on September 15, 2022 at 17:00 CEST.

Joint Global Coordinators and Joint Bookrunners

Credit Suisse

CLSA

CICC

Joint Bookrunners

China Galaxy International

Huatai International

Haitong International

The date of this Supplement is September 15, 2022.

IMPORTANT INFORMATION ABOUT THE OFFERING

The Company, with its registered office at No. 37 Chaoqian Road, Changping District, Beijing, China, assumes responsibility for the completeness and accuracy of the information in the Prospectus and any supplement. The Company confirms that, to the best of its knowledge, the information contained in the Prospectus (including this Supplement) is correct and that no material facts or circumstances have been omitted.

The Prospectus (including this Supplement) has been prepared in accordance with FinSA and its implementing ordinance for the purposes of offering the GDRs and listing the GDRs on SIX Swiss Exchange in accordance with the Standard for Depository Receipts.

The information contained in the Prospectus (including this Supplement) has been provided by the Company and by the other sources identified in the Prospectus (including this Supplement). No representation or warranty, express or implied, is made by the Managers or any of their respective representatives, affiliates or advisors as to the accuracy, completeness or verification of this information set forth in the Prospectus (including this Supplement), and nothing contained in the Prospectus (including this Supplement) is, or shall be relied upon as, a promise or representation in this respect, whether as to the past or the future, by the Managers or by their respective representatives, affiliates or advisors. The Managers assume no responsibility for its accuracy, completeness or verification and accordingly disclaim, to the fullest extent permitted by applicable law, any and all liability whether arising in tort, contract or otherwise which they might otherwise be found to have in respect of the Prospectus (including this Supplement) or any such statement.

The Prospectus (including this Supplement) is not intended to provide the basis of any credit or other evaluation and should not be considered as a recommendation by any of the Company, the Managers nor any of their respective affiliates that any recipient of the Prospectus (including this Supplement) should subscribe for the Offer GDRs. Each potential subscriber of Offer GDRs should determine for itself the relevance of the information contained in the Prospectus (including this Supplement), and its subscription for the Offer GDRs should be based upon such investigation, as it deems necessary, including the assessment of risks involved and its own determination of the suitability of any such investment, with particular reference to their own investment objectives and experience and any other factors that may be relevant to such potential subscriber in connection with the subscription for the Offer GDRs.

As the Company's A Shares are listed on the Shenzhen Stock Exchange, the Company has been subject to periodic reporting and other information disclosure requirements in the PRC. As a result, from time to time, the Group publicly releases information relating to itself on the Shenzhen Stock Exchange or other media outlets designated by the China Securities Regulatory Commission. However, the information announced by the Company in connection with its A Shares is based on the regulatory requirements of the securities authorities and market practice in the PRC, which are different from those which will be applicable to the GDRs following the listing of the Offer GDRs on SIX Swiss Exchange. Such information does not and will not form a part of the Prospectus (including this Supplement). As a result, prospective investors in the Offering are reminded that, in making their investment decision as to whether to purchase the Offer GDRs, they should rely only on the financial, operating and other information included in the Prospectus (including this Supplement). By applying to purchase Offer GDRs in the Offering, prospective investors will be deemed to have agreed that they will not rely on any information other than that contained in the Prospectus (including this Supplement) and any formal announcements made by the Group in the PRC with respect to the Offering.

The Prospectus (including this Supplement) does not constitute: (i) an offer to sell, or a solicitation of an offer to buy any securities other than the securities to which it relates; or (ii) an offer to sell, or the solicitation of an offer to buy, such securities by any person in any circumstances in which such offer or solicitation is unlawful.

The information contained in the Prospectus (including this Supplement) is accurate only as of its date. Neither the delivery of the Prospectus (including this Supplement) nor any sale made hereunder shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since the date hereof or that the information contained herein is correct as of any time subsequent to its date. Any significant new factor or material inaccuracy related to the information

included in the Prospectus (including this Supplement) which is capable of affecting the assessment of the GDRs and which arises or is noted between the date of the Prospectus (including this Supplement) and the First Day of Trading or, as the case may be, the time when trading in the GDRs on SIX Swiss Exchange begins, will be announced through electronic media or through a supplement (if required). Notices required under the Listing Rules will be published in electronic form on the website of SIX Swiss Exchange (currently <https://www.six-group.com/en/productsservices/the-swiss-stock-exchange/market-data/news-tools/official-notice.html#/1>).

In connection with the Offering, the Managers are not acting for anyone other than the Company. The Managers will not regard any other person (whether or not a recipient of the Prospectus (including this Supplement)) as their respective clients in relation to the Offering and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Offering or any transaction or arrangement referred to herein. No person has been authorized to give any information or to make any representations other than those contained in the Prospectus (including this Supplement) and, if given or made, such information or representations must not be relied upon as having been authorized.

In making an investment decision, investors must rely on their own examination, analysis and investigation of the Company and the terms of the Offering, including the merits and risks involved. Any decision to buy the GDRs should be based solely on the Prospectus (including this Supplement) and any other supplement hereto, taking into account that any summary or description set forth in the Prospectus (including this Supplement) of legal provisions, accounting principles or comparison of such principles, corporate structuring or contractual relationships is for information purposes only and should not be considered to be legal, accounting or tax advice or be otherwise relied on. The Prospectus (including this Supplement) does not contain all the information that would be included in a prospectus for the offering of the GDRs if such offering were registered under the Securities Act or pursuant to the Prospectus Regulation (as defined herein). None of the Company, the Managers or any of their respective representatives, is making any representation to any Offeree or purchaser of GDRs regarding the legality of an investment in the GDRs by such Offeree or purchaser under the laws applicable to such Offeree or purchaser. Each investor should consult with his or her own advisors as to the legal, tax, business, financial and related aspects of a purchase of the GDRs.

Each investor acknowledges that: (i) it has not relied on the Managers or any person affiliated with the Managers in connection with any investigation of the accuracy of any information contained in the Prospectus (including this Supplement) or its investment decision; (ii) it has relied only on the information contained in the Prospectus (including this Supplement); and (iii) no person has been authorized to give any information or to make any representation concerning the Company, its subsidiaries or the GDRs (other than as contained in the Prospectus (including this Supplement)) and, if given or made, any such other information or representation had not been relied upon as having been authorized by the Company or the Managers or any of their respective affiliates.

Subject to the allocation directive for the new issue market issued by the Swiss Bankers Association on March 29, 2004, which entered into legal force on January 1, 2005, as amended in January 2008, each of the Managers and any of their respective affiliates, acting as an investor for its own account, may, in connection with the Offering, take up a portion of the Offer GDRs in the Offering as a principal position and in that capacity may retain, purchase or sell for its own account such GDRs and any GDRs or related investments and may offer or sell such GDRs or other investments otherwise than in connection with the Offering. Accordingly, references in the Prospectus (including this Supplement) to Offer GDRs being offered or placed should be read as including any offering or placement of GDRs to any of the Managers or any of their respective affiliates acting in such capacity. None of the Managers intends to disclose the extent of any such investment or transactions, otherwise than in accordance with any legal or regulatory obligation to do so.

AVAILABILITY OF INFORMATION

Copies of the Prospectus (including this Supplement) and any other supplements to the Prospectus are/will be available free of charge in Switzerland for 12 months following the First Day of Trading on SIX Swiss Exchange at Credit Suisse AG, Zurich, Switzerland (email: equity.prospectus@credit-suisse.com). In addition, copies of the Prospectus (including this Supplement) and any other supplements to the Prospectus are/will be available free of charge from Lepu Medical Technology (Beijing) Co., Ltd., No. 37 Chaoqian Road, Changping District, Beijing, the PRC (email: zqb@lepumedical.com).

Information on the Company's website, any website directly or indirectly linked to the Company's website or any website mentioned in the Prospectus (including this Supplement) does not constitute in any way part of the Prospectus (including this Supplement) and is not incorporated by reference into the Prospectus (including this Supplement), and investors should not rely on it in making their decision to invest in the Offer GDRs.

For so long as any of the GDRs are "restricted securities" within the meaning of Rule 144(a)(3) under the Securities Act and the Company is neither subject to the reporting requirements under Sections 13 or 15(d) of the US Securities Exchange Act of 1934, as amended, nor exempt from reporting pursuant to Rule 12g3-2(b) thereunder, the Company will furnish to any holder or beneficial owner of the restricted GDRs, or to any prospective purchaser of such restricted GDRs designated by any such holder or beneficial owner, the information required to be delivered to such persons pursuant to Rule 144A(d)(4) under the Securities Act upon request of any such person. Alternatively, such information can be accessed electronically on the website of the Company at <http://en.lepumedical.com>.

CERTAIN RESTRICTIONS

The distribution of the Prospectus (including this Supplement) and the Offering are restricted by law in certain jurisdictions. Therefore, persons into whose possession the Prospectus (including this Supplement) comes and persons who would like to purchase Offer GDRs pursuant to the Offering should inform themselves about and observe such restrictions. Any failure to comply with such restrictions may constitute a violation of the securities law of any such jurisdiction.

The offer of the Offer GDRs may be affected by the laws of the jurisdictions in which the offerees are located. No action has been or will be taken in any jurisdiction that would permit a public offering of the Offer GDRs or the possession, circulation or distribution of the Prospectus (including this Supplement) or any other material relating to the Company or Offer GDRs hereby in any jurisdiction where action for that purpose is required. Accordingly, the Offer GDRs may not be sold, directly or indirectly, and neither the Prospectus (including this Supplement) nor any other offering material or advertisement in connection with the Offer GDRs may be distributed or published, in any form or in any country or jurisdiction except under circumstances that will result in compliance with any applicable laws, rules and regulations of any such country or jurisdiction. Prospective investors should consult their professional advisors as to whether they require any governmental or other consents or need to observe any formalities to enable them to exercise, purchase, subscribe, or otherwise acquire Offer GDRs in the Offering. None of the Company or the Managers or any of its or their respective representatives, affiliates or advisors accept any legal responsibility for any violation of applicable securities laws.

Each Offeree, by accepting delivery of the Prospectus (including this Supplement), will be deemed to have acknowledged, represented to and agreed with the Company and the Managers as follows:

- (i) the Prospectus (including this Supplement) is personal to such Offeree and does not constitute an offer to any other person, or to the public generally, to purchase or otherwise acquire the Offer GDRs. Distribution of the Prospectus (including this Supplement) or disclosure of any of its contents to any person other than such Offeree and those persons, if any, retained to advise such Offeree with respect thereto is unauthorized, and any disclosure of any of its contents, without the prior written consent of the Joint Global Coordinators, is prohibited;
- (ii) the Offeree will not make any photocopies or electronic copies of the Prospectus (including this Supplement) or any documents referred to herein (other than for its own use); and
- (iii) the Offeree will not forward or deliver the Prospectus (including this Supplement) (in any form) electronically or otherwise, to any other person or reproduce such Prospectus (including this Supplement) in any manner whatsoever.